KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Revenue (2016 - 2025)

Historic Revenue for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $451.8 million.

  • Halozyme Therapeutics' Revenue rose 5159.56% to $451.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4 billion, marking a year-over-year increase of 3755.32%. This contributed to the annual value of $1.4 billion for FY2025, which is 3755.32% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Revenue of $451.8 million as of Q4 2025, which was up 5159.56% from $354.3 million recorded in Q3 2025.
  • Halozyme Therapeutics' 5-year Revenue high stood at $451.8 million for Q4 2025, and its period low was $89.0 million during Q1 2021.
  • In the last 5 years, Halozyme Therapeutics' Revenue had a median value of $212.5 million in 2022 and averaged $217.2 million.
  • Examining YoY changes over the last 5 years, Halozyme Therapeutics' Revenue showed a top increase of 25111.62% in 2021 and a maximum decrease of 1618.69% in 2021.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Revenue stood at $102.0 million in 2021, then soared by 77.93% to $181.5 million in 2022, then increased by 26.75% to $230.0 million in 2023, then increased by 29.55% to $298.0 million in 2024, then surged by 51.6% to $451.8 million in 2025.
  • Its last three reported values are $451.8 million in Q4 2025, $354.3 million for Q3 2025, and $325.7 million during Q2 2025.